Literature DB >> 10029371

Radiation-induced enterocolitis: basic and applied science.

S Szabo1, Z Sandor, A Vincze, Z Gombos, A Mohiuddin, T Viravathana.   

Abstract

We adapted and introduced in our laboratory a simplified animal model of radiation-induced enterocolitis. After a shielding of the parenchymatous organs, our dose-response studies revealed that 20 Gy x-ray radiation resulted in about 20% mortality and reproducible lesions in the terminal ileum and proximal colon. These changes are optimal for pharmacologic studies since they may be decreased or aggravated by drugs. Sucralfate dose-dependently decreased the clinical signs of enterocolitis (e.g., lethargy, diarrhea) as well as the number and area of ileal and colonic erosions and ulcers. The wet weight of the ileum and colon were also decreased by sucralfate. bFGF at the small doses used exerted a beneficial effect only on a few of the parameters of enterocolitis. Thus sucralfate, and maybe bFGF, might decrease the severity and accelerate the healing of radiation-induced enterocolitis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10029371     DOI: 10.1080/11024159850191508

Source DB:  PubMed          Journal:  Eur J Surg Suppl        ISSN: 1102-416X


  3 in total

1.  A case of severe protein-losing enteropathy as a late complication of pelvic irradiation.

Authors:  Wee Sik Sohn; Duck Ryung Kim; Jong Sin Lee; Gi Jeong Cheon; Byung-Hee Lee; Seung-Sook Lee; Sook-Hyang Jeong
Journal:  Korean J Intern Med       Date:  2004-12       Impact factor: 2.884

2.  The protective effects of Resveratrol against radiation-induced intestinal injury.

Authors:  Heng Zhang; Hao Yan; Xiaoliang Zhou; Huaqing Wang; Yiling Yang; Junling Zhang; Hui Wang
Journal:  BMC Complement Altern Med       Date:  2017-08-16       Impact factor: 3.659

3.  Protective effect of genistein on radiation-induced intestinal injury in tumor bearing mice.

Authors:  Tae Gen Son; Eun Ji Gong; Min Ji Bae; Sung Dae Kim; Kyu Heo; Changjong Moon; Kwangmo Yang; Joong Sun Kim
Journal:  BMC Complement Altern Med       Date:  2013-05-14       Impact factor: 3.659

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.